Orbimed Advisors LLC Prelude Therapeutics Inc Transaction History
Orbimed Advisors LLC
- $3.69 Billion
- Q4 2024
A detailed history of Orbimed Advisors LLC transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Orbimed Advisors LLC holds 10,909,256 shares of PRLD stock, worth $8.18 Million. This represents 0.38% of its overall portfolio holdings.
Number of Shares
10,909,256
Previous 10,909,256
-0.0%
Holding current value
$8.18 Million
Previous $22.6 Million
38.65%
% of portfolio
0.38%
Previous 0.53%
Shares
3 transactions
Others Institutions Holding PRLD
# of Institutions
59Shares Held
30.4MCall Options Held
6.4KPut Options Held
0-
Baker Bros. Advisors LP New York, NY10.1MShares$7.59 Million0.14% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$801,6870.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.03MShares$771,8990.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.01MShares$757,7940.0% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ667KShares$499,9300.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $27.3M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...